CORAL GABLES, Fla., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc.
(Nasdaq:CPRX) announced today that the company will present at the 15th Annual BIO CEO & Investor
Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Patrick J.
McEnany, Catalyst's Chief Executive Officer and Steven Miller, PhD, Catalyst's Chief Scientific
Officer/COO, will provide an overview of the company and its progress in key programs on Monday,
February 11, 2013, at 4:00 p.m. Eastern Standard Time. The company's presentation materials will
be posted at the company's website, http://www.catalystpharma.com
, in the Investors section, under "Events and Presentations".
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the
development and commercialization of prescription drugs targeting rare (orphan) neurological
diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and
Tourette Syndrome. Catalyst's lead candidate, Firdapse for the treatment of LEMS, is currently
undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing
a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat
infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette Syndrome, and movement
disorders associated with the treatment of Parkinson's Disease.
This press release contains forward-looking statements. Forward-looking statements involve known
and unknown risks and uncertainties, which may cause the Company's actual results in future
periods to differ materially from forecasted results. A number of factors, including whether any
of the Company's product candidates will ever be approved for commercialization and those factors
described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could
adversely affect the Company. Copies of the Company's filings with the SEC are available from the
SEC, may be found on the Company's website or may be obtained upon request from the Company. The
Company does not undertake any obligation to update the information contained herein, which speaks
only as of this date.
CONTACT: Patrick J. McEnany
Catalyst Pharmaceutical Partners
Chief Executive Officer
Rx Communications Group